Sufentanil Hybrid Receives CHMP Nod for Post-Op Pain

Miriam E. Tucker

Disclosures

July 24, 2015

Sufentanil (Zalviso, Grunenthal GmbH) has received a European government endorsement for the treatment of postoperative pain.

The positive opinion, from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), is for a hybrid medicine: a drug that is similar to an authorized medicine containing the same active substance, but that differs in characteristics such as strength, indication, or pharmaceutical form.

Zalviso is a hybrid of Sufenta (Akorn), which has been authorized in the Netherlands since 1978 as an anaesthetic-analgesic. Hybrid applications include data from studies on the new product as well as for a reference product.

The active ingredient, sufentanil, is an opioid that produces analgesia via activation of μ-opioid receptors primarily within the central nervous system. The full indication of the product, which will be sold as 15-μg sublingual tablets, is: "Zalviso is indicated for the management of acute moderate to severe post-operative pain in adult patients."

The most common adverse effects are nausea, vomiting, fever, and headache.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....